Novopyxis
Daniel Vannoni has a diverse work experience, starting with founding Housequarters in 2012, where they served as the Founder and Chief Doer. At Housequarters, they provided various services related to homeownership. In 2013, they became the Chairman and Co-Founder of Novopyxis, a company focused on finding treatments for chronic medical conditions. Daniel led the company as the founding CEO and guided it towards commercialization. Daniel Vannoni also served as an investor in Franklin Robotics and Droplette. Daniel worked as an Entrepreneur and Managing Director at Gecko Ventures starting in 2011. Additionally, they served on the Board of Directors for MIT $100K Entrepreneurship Competition and acted as the Chair from 2011 to 2012. In 2013, they founded Iggy, a company that aimed to personalize the real world using technology. Daniel also served as a Board of Director/Advisor at CoolChip Technologies from 2011 to 2015. In 2013, they co-founded QuackTax LLC, which aimed to help small business owners understand and manage their taxes effectively. Lastly, Daniel Vannoni co-founded MJFF Data Challenge at The Michael J. Fox Foundation for Parkinson's Research. Daniel played a role in translating data collected from patients into a contest to find innovative ways to treat Parkinson's disease.
Daniel Vannoni has an educational background that includes various degrees and certifications. Daniel holds an MBA and a Certificate in Entrepreneurship & Innovation from the MIT Sloan School of Management. Prior to that, they completed their BA in Economics & Sociology at Bates College. Daniel also has experience studying Italian, with coursework at the Università per Stranieri di Perugia and the Umbra Institute. In terms of their earlier education, they attended Boston College High School for their high school education. Additionally, Daniel has obtained several certifications, including Lead-Safe Renovator, Massachusetts Construction Supervisor License (Unrestricted), Massachusetts Home Improvement Contractor License, Massachusetts Insurance Producer License, Massachusetts Real Estate Broker License, and Notary Public, all from the Commonwealth of Massachusetts.
This person is not in the org chart
This person is not in any teams
Novopyxis
Novopyxis is an award-winning biotechnology company dedicated to the development of therapeutics and medical devices. Novopyxis’ flagship drug was developed using in-house proprietary mathematical algorithms and has been validated across several different in vitro, ex vivo, and in vivo models. It activates a key anti-inflammatory receptor calledthe AT2R and is both cardioprotective and neuroprotective. Their therapeutic was recently awarded an orphan designation for "Pediatric Cardiomyopathy" from the FDA. Droplette was recently spun out from Novopyxis (www.droplette.io) and is focused on the development of a patented medical device for the delivery of large molecules, DNA/RNA, and proteins deep through skin, tissue, and cells. They are currently partnered with Leo Pharma for the development of their device for medical dermatology applications and have won several awards including the 2015 Graduate of MassCONNECT program via MassBio, 2015 Amgen Golden Ticket Winner, 2014 Mass Challenge Finalist, Winner of 2014 CASIS-Boeing Prize for Technology in Space, and Second place winner in 2015 M2D2 New Ventures Competition